These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
634 related articles for article (PubMed ID: 17653893)
21. Peptide Receptor Radionuclide Therapy for Advanced Gastroenteropancreatic Neuroendocrine Tumors - from oncology perspective. Kolasińska-Ćwikła A; Łowczak A; Maciejkiewicz KM; Ćwikła JB Nucl Med Rev Cent East Eur; 2018; 21(2):. PubMed ID: 29741203 [TBL] [Abstract][Full Text] [Related]
22. Therapy using labelled somatostatin analogues: comparison of the absorbed doses with 111In-DTPA-D-Phe1-octreotide and yttrium-labelled DOTA-D-Phe1-Tyr3-octreotide. Barone R; Walrand S; Konijnenberg M; Valkema R; Kvols LK; Krenning EP; Pauwels S; Jamar F Nucl Med Commun; 2008 Mar; 29(3):283-90. PubMed ID: 18349800 [TBL] [Abstract][Full Text] [Related]
23. Molecular imaging as in vivo molecular pathology for gastroenteropancreatic neuroendocrine tumors: implications for follow-up after therapy. Krenning EP; Valkema R; Kwekkeboom DJ; de Herder WW; van Eijck CH; de Jong M; Pauwels S; Reubi JC J Nucl Med; 2005 Jan; 46 Suppl 1():76S-82S. PubMed ID: 15653655 [TBL] [Abstract][Full Text] [Related]
24. Somatostatin receptor-targeted radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors. Kwekkeboom DJ; de Herder WW; Krenning EP Endocrinol Metab Clin North Am; 2011 Mar; 40(1):173-85, ix. PubMed ID: 21349418 [TBL] [Abstract][Full Text] [Related]
30. Comparison of the Therapeutic Response to Treatment with a 177Lu-Labeled Somatostatin Receptor Agonist and Antagonist in Preclinical Models. Dalm SU; Nonnekens J; Doeswijk GN; de Blois E; van Gent DC; Konijnenberg MW; de Jong M J Nucl Med; 2016 Feb; 57(2):260-5. PubMed ID: 26514177 [TBL] [Abstract][Full Text] [Related]
31. Long-Term Efficacy, Survival, and Safety of [ Brabander T; van der Zwan WA; Teunissen JJM; Kam BLR; Feelders RA; de Herder WW; van Eijck CHJ; Franssen GJH; Krenning EP; Kwekkeboom DJ Clin Cancer Res; 2017 Aug; 23(16):4617-4624. PubMed ID: 28428192 [No Abstract] [Full Text] [Related]
32. Peptide receptor radionuclide therapy of neuroendocrine tumours. Brabander T; Teunissen JJ; Van Eijck CH; Franssen GJ; Feelders RA; de Herder WW; Kwekkeboom DJ Best Pract Res Clin Endocrinol Metab; 2016 Jan; 30(1):103-14. PubMed ID: 26971847 [TBL] [Abstract][Full Text] [Related]
33. Peptide receptor radionuclide therapy with somatostatin analogues in neuroendocrine tumors. Giovacchini G; Nicolas G; Forrer F Anticancer Agents Med Chem; 2012 Jun; 12(5):526-42. PubMed ID: 22292758 [TBL] [Abstract][Full Text] [Related]
34. Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-octreotate. Ezziddin S; Attassi M; Yong-Hing CJ; Ahmadzadehfar H; Willinek W; Grünwald F; Guhlke S; Biersack HJ; Sabet A J Nucl Med; 2014 Feb; 55(2):183-90. PubMed ID: 24434296 [TBL] [Abstract][Full Text] [Related]
35. [177Lu-DOTA(0),Tyr3] octreotate for somatostatin receptor-targeted radionuclide therapy. de Jong M; Breeman WA; Bernard BF; Bakker WH; Schaar M; van Gameren A; Bugaj JE; Erion J; Schmidt M; Srinivasan A; Krenning EP Int J Cancer; 2001 Jun; 92(5):628-33. PubMed ID: 11340564 [TBL] [Abstract][Full Text] [Related]